Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InMode Ltd. stock logo
INMD
InMode
$13.74
+0.6%
$14.33
$13.14
$19.85
$863.44M1.951.02 million shs1.73 million shs
Envista Holdings Corporation stock logo
NVST
Envista
$20.78
+10.0%
$19.41
$14.22
$23.00
$3.20B12.23 million shs6.20 million shs
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$49.96
+3.0%
$58.32
$47.04
$103.81
$2.68B1.071.12 million shs1.28 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$120.55
+1.3%
$124.51
$55.00
$177.37
$4.06B2.091.20 million shs1.78 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InMode Ltd. stock logo
INMD
InMode
+0.59%-6.66%-9.66%-5.70%-24.17%
Envista Holdings Corporation stock logo
NVST
Envista
+10.03%-0.12%+2.97%+22.45%+21.73%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
+2.99%-10.34%-14.13%-10.18%-21.10%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+1.33%+11.50%-5.59%+33.97%-15.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InMode Ltd. stock logo
INMD
InMode
3.0833 of 5 stars
3.14.00.00.01.81.71.9
Envista Holdings Corporation stock logo
NVST
Envista
4.015 of 5 stars
2.22.00.03.83.80.03.1
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.6459 of 5 stars
3.41.00.00.03.92.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.4781 of 5 stars
2.42.00.00.02.82.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InMode Ltd. stock logo
INMD
InMode
2.13
Hold$18.0431.31% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.920.69% Upside
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.78
Moderate Buy$84.1368.38% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.78
Moderate Buy$123.002.03% Upside

Current Analyst Ratings Breakdown

Latest INMD, TMDX, NVST, and PRCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$15.00 ➝ $18.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $19.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $17.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $19.00
8/1/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.00
7/30/2025
InMode Ltd. stock logo
INMD
InMode
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
7/30/2025
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.00
7/29/2025
Envista Holdings Corporation stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$18.00 ➝ $22.00
7/15/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $68.00
7/15/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$129.00 ➝ $142.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InMode Ltd. stock logo
INMD
InMode
$401.56M2.16$1.83 per share7.49$9.94 per share1.38
Envista Holdings Corporation stock logo
NVST
Envista
$2.51B1.40$1.83 per share11.37$17.05 per share1.22
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$249.12M11.10N/AN/A$7.71 per share6.48
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M9.31$1.67 per share72.31$9.33 per share12.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InMode Ltd. stock logo
INMD
InMode
$181.27M$2.475.567.55N/A44.50%18.38%16.35%N/A
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B-$6.5364.9417.171.192.11%4.89%2.71%N/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%8/6/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9362.4684.30N/A13.49%28.02%8.64%N/A

Latest INMD, TMDX, NVST, and PRCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$0.41N/AN/AN/A$75.67 millionN/A
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
InMode Ltd. stock logo
INMD
InMode
$0.50$0.47-$0.03$0.42$98.45 million$95.60 million
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InMode Ltd. stock logo
INMD
InMode
N/A
9.60
7.86
Envista Holdings Corporation stock logo
NVST
Envista
0.43
2.12
1.82
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
0.13
8.95
7.75
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
8.32

Institutional Ownership

CompanyInstitutional Ownership
InMode Ltd. stock logo
INMD
InMode
68.04%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
89.46%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
InMode Ltd. stock logo
INMD
InMode
6.92%
Envista Holdings Corporation stock logo
NVST
Envista
1.30%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
6.60%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
InMode Ltd. stock logo
INMD
InMode
48063.21 million58.84 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300169.49 million167.28 millionOptionable
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
43055.33 million51.68 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.46 millionOptionable

Recent News About These Companies

TransMedics Group (NASDAQ:TMDX) Shares Gap Up After Earnings Beat
TransMedics: Continued Strength Suggests Further Upside
TransMedics (TMDX) Q2 Revenue Jumps 38%
TransMedics Sees Its Earnings Soar
TransMedics Reports Second Quarter 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

InMode stock logo

InMode NASDAQ:INMD

$13.74 +0.08 (+0.59%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$13.85 +0.11 (+0.80%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Envista stock logo

Envista NYSE:NVST

$20.78 +1.89 (+10.01%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$20.80 +0.02 (+0.07%)
As of 08/1/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

PROCEPT BioRobotics stock logo

PROCEPT BioRobotics NASDAQ:PRCT

$49.96 +1.45 (+2.99%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$50.94 +0.98 (+1.96%)
As of 08/1/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$120.55 +1.58 (+1.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$121.16 +0.62 (+0.51%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.